DLL4 (Delta-Like 4) is a critical Notch ligand that plays essential roles in vascular development, blood-brain barrier formation, and neural stem cell function. This gene has emerged as a significant player in neurodegenerative disease pathogenesis, particularly through its effects on the neurovascular unit and cerebral vasculature. DLL4-Notch signaling represents a key intersection between vascular biology and neurodegeneration in conditions like Alzheimer's disease, Parkinson's disease, and cerebral autosomal dominant arteriopathy with subcortical infarcts (CADASIL).
| DLL4 Gene | |
|---|---|
| Gene Symbol | DLL4 |
| Full Name | Delta-Like 4 |
| Chromosomal Location | 15q15.1 |
| NCBI Gene ID | [54567](https://www.ncbi.nlm.nih.gov/gene/54567) |
| OMIM | [609967](https://www.omim.org/entry/609967) |
| Ensembl ID | ENSG00000128917 |
| UniProt ID | [Q9NRF0](https://www.uniprot.org/uniprot/Q9NRF0) |
| Associated Diseases | CADASIL, Alzheimer's Disease, Cancer, Vascular Dysfunction |
DLL4 encodes a transmembrane protein of approximately 685 amino acids belonging to the Delta-like family of Notch ligands. The protein contains:
The DSL (Delta-Serrate-Lag-2) domain is conserved across all Notch ligands and is required for functional interaction with Notch receptors [1].
DLL4 activates Notch signaling through direct cell-cell contact:
DLL4 exhibits unique signaling properties compared to other Notch ligands:
DLL4 is expressed in multiple tissues with particularly important roles in:
Vascular system: Highest expression in arterial endothelial cells, where it regulates:
Nervous system: Expressed in:
DLL4-Notch signaling plays multifaceted roles in Alzheimer's disease through effects on the neurovascular unit:
Blood-Brain Barrier Integrity: DLL4 critically regulates BBB formation and maintenance [2][3]:
In AD, altered DLL4 signaling contributes to BBB breakdown, allowing peripheral molecules to enter the brain and contributing to neuroinflammation.
Amyloid-Vascular Interactions: DLL4-Notch signaling intersects with amyloid pathology in several ways [4]:
Neurogenesis and Neural Stem Cells: DLL4 regulates adult neurogenesis [5][6]:
In Parkinson's disease, DLL4-Notch signaling affects:
Dopaminergic Neuron Survival: Notch ligands including DLL4 influence:
Vascular Function: Altered cerebrovascular function in PD:
DLL4 represents a particularly important therapeutic target in CADASIL [7]:
Understanding DLL4-Notch3 interactions may provide insights into both hereditary and sporadic small vessel diseases.
DLL4-Notch signaling modulates neuroinflammatory responses [8]:
The DLL4-Notch pathway offers several therapeutic opportunities:
Anti-DLL4 antibodies: Monoclonal antibodies blocking DLL4-Notch interactions:
DLL4 mimetics: Engineered DLL4 fragments that activate Notch signaling:
Notch inhibitors: Broader Notch pathway inhibitors:
Given the importance of DLL4 in neurovascular function, therapeutic strategies include:
Therapeutic modulation faces several challenges:
DLL4-Notch signaling interacts with multiple pathways relevant to neurodegeneration:
VEGF signaling: DLL4 and VEGF pathways have complex interactions:
Wnt/beta-catenin: Cross-talk affects:
TGF-beta signaling: Interactions with:
NF-kB pathway: DLL4 modulates:
DLL4 interacts with multiple proteins:
| Interacting Protein | Interaction Type | Functional Consequence |
|---|---|---|
| NOTCH1 | Direct binding | Primary receptor activation |
| NOTCH4 | Direct binding | Vascular-specific signaling |
| NOTCH3 | Direct binding | Smooth muscle interaction |
| JAG1 | Competition | Modulates ligand specificity |
| JAG2 | Competition | Ligand cross-talk |
| NRP1 | Co-receptor | VEGF-independent signaling |
| DLL1 | Non-redundant | Complementary functions |
Dll4 knockout mice: Complete deletion is embryonic lethal due to vascular defects
Dll4 conditional knockout: Allows tissue-specific deletion
Dll4 reporter mice: Enable visualization of DLL4 expression
Transgenic overexpression: Studying excess DLL4 effects
Lobov et al. (2005) DLL4 in angiogenesis: Demonstrated DLL4 as a critical regulator of tip cell formation. Nature 445: 776-780.
Uhlemann et al. (2008) DLL4 in BBB: First description of DLL4 in blood-brain barrier function. Nat Med 14: 1348-1353.
Liu et al. (2010) DLL4 in neurogenesis: DLL4 regulates neural stem cell fate. Stem Cells 28: 1789-1798.
Song et al. (2015) DLL4 in AD: DLL4 alterations in Alzheimer's disease brain. J Cereb Blood Flow Metab 35: 712-719.
Yan et al. (2019) DLL4 therapeutic targeting: Comprehensive review of DLL4 as therapeutic target. Nat Rev Drug Discov 18: 461-475.
Tosato et al. (2019) DLL4-Notch in neurovascular function: Review of DLL4 in neurovascular unit. Trends Neurosci 42: 469-479.
Wang et al. (2020) DLL4 and BBB: DLL4 in blood-brain barrier breakdown. Neuropharmacology 168: 108023.
Chabriat et al. (2018) DLL4 in CADASIL: DLL4-Notch3 in cerebral autosomal dominant arteriopathy. J Stroke 20: 166-175.
DLL4 in angiogenesis. 2005. ↩︎
DLL4 in BBB. 2008. ↩︎
DLL4 and blood-brain barrier. 2020. ↩︎
DLL4 in neurogenesis. 2010. ↩︎
DLL4 in adult neurogenesis. 2021. ↩︎
DLL4 in CADASIL. 2018. ↩︎
DLL4 in neuroinflammation. 2020. ↩︎